Terms: = Lung cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR AND Treatment
63 results:
1. Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.
Hosni S; Kilian V; Klümper N; Gabbia D; Sieckmann K; Corvino D; Winkler A; Saponaro M; Wörsdörfer K; Schmidt D; Hahn O; Zanotto I; Bertlich M; Toma M; Bald T; Eckstein M; Hölzel M; Geyer M; Ritter M; Wachten D; De Martin S; Alajati A
Cancer Res; 2024 Mar; 84(5):725-740. PubMed ID: 38175774
[TBL] [Abstract] [Full Text] [Related]
2. Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases.
Roskoski R
Pharmacol Res; 2024 Jan; 199():107036. PubMed ID: 38096958
[TBL] [Abstract] [Full Text] [Related]
3. FGF2 drives osteosarcoma metastasis through activating FGFR1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
4. Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs.
Pace A; Scirocchi F; Napoletano C; Zizzari IG; Po A; Megiorni F; Asquino A; Pontecorvi P; Rahimi H; Marchese C; Ferretti E; Nuti M; Rughetti A
J Transl Med; 2023 Sep; 21(1):626. PubMed ID: 37715207
[TBL] [Abstract] [Full Text] [Related]
5. Genome-wide Detection of Chimeric Transcripts in Early-stage Non-small Cell lung cancer.
Ilnytskyy Y; Petersen L; McIntyre JB; Konno M; D'Silva A; Dean M; Elegbede A; Golubov A; Kovalchuk O; Kovalchuk I; Bebb G
Cancer Genomics Proteomics; 2023; 20(5):417-432. PubMed ID: 37643782
[TBL] [Abstract] [Full Text] [Related]
6. Detecting undetectable - epidemiology, etiology, and diagnosis of carcinoma of unknown primary - systematic review.
Ostojewska J; Wieczorek I; Pachciński O; Zdziennicki W; Burdan F
Folia Med Cracov; 2023 Apr; 63(1):19-37. PubMed ID: 37406274
[TBL] [Abstract] [Full Text] [Related]
7. lung cancer presenting with central nervous system metastasis: Clinicopathological and molecular analysis of 171 cases.
Demleitner M; Erlenbach-Wünsch K; Coras R; Erber R; Polifka I; Eyüpoğlu I; Fuchs F; Hartmann A; Agaimy A
Ann Diagn Pathol; 2023 Apr; 63():152082. PubMed ID: 36634550
[TBL] [Abstract] [Full Text] [Related]
8. Futibatinib: First Approval.
Syed YY
Drugs; 2022 Dec; 82(18):1737-1743. PubMed ID: 36441501
[TBL] [Abstract] [Full Text] [Related]
9. Clinical and molecular characteristics of kinase domain duplications across diverse cancer types in the Chinese population.
Lai X; Yu R; Ou Q; Bao H; Wu X; Shao Y; Li Y; Zhang Y; Ding Q
Cancer Med; 2023 Mar; 12(5):6009-6015. PubMed ID: 36325957
[TBL] [Abstract] [Full Text] [Related]
10. Targeted profiling of human extrachromosomal DNA by CRISPR-CATCH.
Hung KL; Luebeck J; Dehkordi SR; Colón CI; Li R; Wong IT; Coruh C; Dharanipragada P; Lomeli SH; Weiser NE; Moriceau G; Zhang X; Bailey C; Houlahan KE; Yang W; González RC; Swanton C; Curtis C; Jamal-Hanjani M; Henssen AG; Law JA; Greenleaf WJ; Lo RS; Mischel PS; Bafna V; Chang HY
Nat Genet; 2022 Nov; 54(11):1746-1754. PubMed ID: 36253572
[TBL] [Abstract] [Full Text] [Related]
11. FGFR1-4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell lung cancer.
Moes-Sosnowska J; Skupinska M; Lechowicz U; Szczepulska-Wojcik E; Skronska P; Rozy A; Stepniewska A; Langfort R; Rudzinski P; Orlowski T; Popiel D; Stanczak A; Wieczorek M; Chorostowska-Wynimko J
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142417
[TBL] [Abstract] [Full Text] [Related]
12. Gastric carcinosarcoma with fgfr2 amplification under long-term control with pazopanib: a case report and literature review.
Hayashi H; Makiyama A; Okumura N; Yasufuku I; Saigo C; Takeuchi T; Miyazaki T; Tanaka Y; Matsuhashi N; Murase K; Takahashi T; Futamura M; Yoshida K
BMC Gastroenterol; 2022 Jul; 22(1):360. PubMed ID: 35902814
[TBL] [Abstract] [Full Text] [Related]
13. Diverse alterations associated with resistance to KRAS(G12C) inhibition.
Zhao Y; Murciano-Goroff YR; Xue JY; Ang A; Lucas J; Mai TT; Da Cruz Paula AF; Saiki AY; Mohn D; Achanta P; Sisk AE; Arora KS; Roy RS; Kim D; Li C; Lim LP; Li M; Bahr A; Loomis BR; de Stanchina E; Reis-Filho JS; Weigelt B; Berger M; Riely G; Arbour KC; Lipford JR; Li BT; Lito P
Nature; 2021 Nov; 599(7886):679-683. PubMed ID: 34759319
[TBL] [Abstract] [Full Text] [Related]
14. Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma.
Tai DWM; Le TBU; Prawira A; Ho RZW; Huynh H
Hepatol Int; 2021 Oct; 15(5):1236-1246. PubMed ID: 34333737
[TBL] [Abstract] [Full Text] [Related]
15. Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in cancer Signaling.
Ferguson HR; Smith MP; Francavilla C
Cells; 2021 May; 10(5):. PubMed ID: 34068954
[TBL] [Abstract] [Full Text] [Related]
16. NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.
Sánchez-Herrero E; Serna-Blasco R; Ivanchuk V; García-Campelo R; Dómine Gómez M; Sánchez JM; Massutí B; Reguart N; Camps C; Sanz-Moreno S; Calabuig-Fariñas S; Jantus-Lewintre E; Arnal M; Fernández-Orth D; Calvo V; González-Rumayor V; Provencio M; Romero A
Mol Oncol; 2021 Sep; 15(9):2363-2376. PubMed ID: 34058070
[TBL] [Abstract] [Full Text] [Related]
17. Poor prognosis of male triple-positive breast cancer patients: a propensity score matched SEER analysis and molecular portraits.
Wang B; Wang H; Zhao A; Zhang M; Yang J
BMC Cancer; 2021 May; 21(1):523. PubMed ID: 33964913
[TBL] [Abstract] [Full Text] [Related]
18. Erdafitinib as a Novel and Advanced treatment Strategy of Metastatic Urothelial Carcinoma.
Bansal P; Dwivedi DK; Hatwal D; Sharma P; Gupta V; Goyal S; Maithani M
Anticancer Agents Med Chem; 2021; 21(18):2478-2486. PubMed ID: 33475078
[TBL] [Abstract] [Full Text] [Related]
19. Association of Osteonecrosis of the Jaw With Zoledronic Acid treatment for Bone Metastases in Patients With cancer.
Van Poznak CH; Unger JM; Darke AK; Moinpour C; Bagramian RA; Schubert MM; Hansen LK; Floyd JD; Dakhil SR; Lew DL; Wade JL; Fisch MJ; Henry NL; Hershman DL; Gralow J
JAMA Oncol; 2021 Feb; 7(2):246-254. PubMed ID: 33331905
[TBL] [Abstract] [Full Text] [Related]
20. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
[TBL] [Abstract] [Full Text] [Related]
[Next]
